Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation - Comparison to CA 125 antigen

European Journal of Gynaecological Oncology

Volumn 30, Issue 6, 2009, Pages 668-671

  Chudecka Glaz A ^a   Gorski B ^a   Zielinska D ^a   Blogowski W ^a   Wojciechowska, I ^a   Bedner, R ^a   Rzepka Gorska I ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Biomarkers; BRCA 1 gene mutaion; CA 125; Ovarian cancer; YKL 40

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; ONCOPROTEIN; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; EPITHELIUM TUMOR; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PROTEIN BLOOD LEVEL;

CA-125 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GLYCOPROTEINS; HUMANS; LECTINS; MUTATION; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70949100982     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C. et al.: "Cancer statistics, 2006". CA Cancer J. Clin., 2006, 56, 106.
2. Schwarc P.E.: "Current diagnosis and treatment modalities for ovarian cancer". Cancer Treat. Res., 2002, 107, 99.
3. Jacobs I.J., Menon U.: "Progress and challenges in screening for early detection of ovarian cancer". Mol. Cell. Proteomics, 2004, 3, 355.
4. Makar A.P., Kristensen G.B., Borner O.P., Trope C.C.: "Is serum CA 125 at time of relapse prognostic indicator for futher survival prognosis in patient with ovarian cancer". Gynecol. Oncol., 1993, 9, 7.
5. Johansen J.S., Williamson M.K., Rice J.S., Price P.A.: "Identification of proteins secreted by human osteoblastic cells in culture". J. Bone Miner. Res., 1992, 7, 501.
6. Pelloski C.E., Mahajan A., Maar M., Chang E.L., Woo S., Gilbert M. et al.: "YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma". Clin. Cancer Res., 2005, 11, 3326. (Pubitemid 40627883)
7. Shackelton L.M., Mann D.M., Mills A.J.T.: "Identification of a 38-kDa heparin-binding glycoproptein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling". J. Biol. Chem., 1995, 270, 13076.
8. Nutt C.L., Betensky R.A., Brower M.A., Batchelor T.T., Luis D.N., Stemmer-Rachmaninov A.O. et al.: "YKL-40 is a differentiated diagnostic marker for histologic subtypes of high-grade gliomas". Clin. Cancer Res., 2005, 11, 2258.
9. Roslind A., Johansen J.S., Junker S.: "YKL-40 expression in breast cancer". Meeting Proceedings of the American Society for Clinical Oncology. ASCO, 2005, 23, 9665.
10. Johansen J.S., Hansen U., Christensen I.J.: "YKL-40 protein expression in cancer cells and macrophages in colorectal cancer". Meeting Proceedings of the American Society for Clinical Oncology ASCO, 2005, 23, 3728.
11. Rzepka-Górska I., Menkiszak J., Chudecka-Głaz A., Górski B., Zielińska D.: "Prophylactic salpingooophorectomy in BRCA 1 mutation carriers". Gin. Onkol. Supl., 2007, 1, 54.
12. Górski B., Jakubowska A., Huzarski T., Byrski T., Gronwald J., Grzybowska E. et al.: "A high proportion of founder BRCA 1 mutations in Polish breast cancer families". Int. J. Cancer, 2004, 110, 683. (Pubitemid 38746026)
13. Górski B., Menkiszak J., Gronwald J., Lubiński J., Narod S.A.: "A protein truncating BRCA 1 allele with a low penetrance of breast cancer". J. Med. Genet., 2004, 41, 130.
14. Tarnowski B., Chudecka-Głaz A., Górski B., Rzepka-Górska I.: "Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA 1 gene in breast cancer patients". Br. Cancer Res. Treat., 2004, 55, 287. (Pubitemid 40137308)
15. Rzepka-Górska I., Tarnowski B., Chudecka-Głaz A., Górski B.: "BRCA 1 mutation, leptin and estrogen levels in breast cancer patients". Eur. J. Gynecol. Oncol., 2005, 26, 205.
16. Rzepka-Górska I., Tarnowski B., Chudecka-Głaz A., Górski B., Zieli ska D., Tołoczko-Grabarek A.: "Premature menopause in patients with BRCA 1 gene mutation". Breast Cancer Res. Treat., 2006, 100, 59.
17. Henrissat B., Bairoch A.: "New families in the classification of glycosyl hydrolases based on amino acid sequence similarities". Biochem. J., 1993, 293, 781. (Pubitemid 23244564)
18. Dupont J., Tanwar M.K., Thaler H.T., Fleischer M., Kauff N., Hensley M.L. et al.: "Early detection and prognosis of ovarian cancer using serum YKL-40". J. Clin. Oncol., 2004, 22, 3330. (Pubitemid 41103690)
19. Stokes D.G., Liu G., Coimbra I.B., Piera-Velazquez S., Crowl R.M., Jimenez S.A.: "Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis". Arthritis Rheum., 2002, 46, 404. (Pubitemid 34136578)
20. Ling H., Recklies A.D.: "The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines intraleukin-1 and tumor necrosis factor-alfa". Biochem. J., 2004, 380, 651. (Pubitemid 38850506)
21. Dehn H., Hogdall E.V.S., Johansen J.S., Jorgensen M., Price P.A., Engelholm S.A. et al.: "Plasma YKL-40 as a prognostic tumor marker in recurrent ovarian cancer". Acta Obstet. Gynecol. Scand., 2003, 82, 287. (Pubitemid 36459738)
22. Hogdall E.V., Johansen J.S., Kjaer S.K., Price P.A., Christensen L., Blaakaer J. et al.: "High plasma YKL-40 level in patients with ovarian cancer Stage III is related to shorter survival". Oncol. Rep., 2003, 10, 1535.
23. Gronlund B., Hogdall E.V., Christensen I.J., Johansen J.S:, Norgaard-Pedersen B., Engelholm S.A. et al.: "Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125)". Int. J. Biol. Markers, 2006, 21, 141. (Pubitemid 44660285)
24. Johansen J.S., Jensen B.V., Roslind A., Nielsen D., Price P.A.: "Serum YKL-40, a new prognostic biomarker in cancer patients?". Cancer Epidemiol Biomarkers Prev., 2006, 15, 194. (Pubitemid 43342164)